EGFR and neoplasm: STAT3-driven tumor progression can also be achieved by epidermal growth factor receptors (both wild-type EGFR and EGFRvIII), fibroblast growth factor receptors (FGFR), insulin-like growth factor receptor (IGFR), hepatocyte growth factor (HGFR, also known as MET), platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor (VEGFR), v-src, and Bcr-Abl [119,120,121,122,123,124,125,126,127].